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Abstract
Background: Streblus asper is a well-known plant native to Southeast Asia. Different parts of the plant have been
traditionally used for various medicinal purposes. However, there is very little scientific evidence reporting its
therapeutic benefits for potential treatment of Alzheimer’s disease (AD). The study aimed to evaluate antibacterial,
antioxidant, acetylcholinesterase (AChE) inhibition, and neuroprotective properties of S. asper leaf extracts with the
primary objective of enhancing therapeutic applications and facilitating activity-guided isolation of the active
chemical constituents.
Methods: The leaves of S. asper were extracted in ethanol and subsequently fractionated into neutral, acid and
base fractions. The phytochemical constituents of each fraction were analyzed using GC-MS. The antibacterial
activity was evaluated using a broth microdilution method. The antioxidant activity was determined using DPPH
and ABTS radical scavenging assays. The neuroprotective activity against glutamate-induced toxicity was tested on
hippocampal neuronal HT22 cell line by evaluating the cell viability using MTT assay. The AChE inhibitory activity
was screened by thin-layer chromatography (TLC) bioautographic method.
Results: The partition of the S. asper ethanolic leaf extract yielded the highest mass of phytochemical constitutions
in the neutral fraction and the lowest in the basic fraction. Amongst the three fractions, the acidic fraction showed
the strongest antibacterial activity against gram-positive bacteria. The antioxidant activities of three fractions were
found in the order of acidic > basic > neutral, whereas the decreasing order of neuroprotective activity was neutral
> basic > acidic. TLC bioautography revealed one component in the neutral fraction exhibited anti-AChE activity.
While in the acid fraction, two components showed inhibitory activity against AChE. GC-MS analysis of three
fractions showed the presence of major phytochemical constituents including terpenoids, steroids, phenolics, fatty
acids, and lipidic plant hormone.
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Conclusions: Our findings have demonstrated the therapeutic potential of three fractions extracted from S. asper
leaves as a promising natural source for neuroprotective agents with additional actions of antibacterials and
antioxidants, along with AChE inhibitors that will benefit in the development of new natural compounds in
therapies against AD.
Keywords: Acid-base extraction, Streblus asper, Glutamate toxicity, HT22 cells, Neuroprotection, Alzheimer’s disease,
Neurodegenerative diseases
Background
Herbal medicines are gaining significant attention globally
in primary health care due to its various advantages over
prescribed synthetic drugs, especially in long-term usage
[1–3]. Synthetic FDA approved drugs, during long-term
usage, may have adverse side effects [4, 5], and are not
cost-effective or readily affordable in under developed and
developing countries [6–10]. The use of medicinal plants
or plant-derived substances in the prevention and treat-
ment of various diseases including Alzheimer’s disease
(AD) has been proven to be effective and is on the rise
[11–15]. Two examples of plant-derived FDA approved
drugs used for the treatment of AD are rivastigmine and
galantamine, which were isolated from Physostigma vene-
nosum and Galanthus caucasicus, respectively [16, 17].
Other promising natural products such as Huperzine A
(derived from Huperzia serrata), curcumin (derived from
Curcuma longa), and resveratrol (derived from Vitis vinif-
era) also possess excellent anti-AD activity and they are in
Phase II or III clinical trials [18, 19]. Moreover, a number
of medicinal plants with antioxidant, anti-inflammatory,
and anti-apoptotic effects are currently being researched
as an excellent source of neuroprotective agents and/or
anti-AD drugs [16, 17, 20–23].
AD is one of the most common neurodegenerative dis-
eases, characterized by the progressive loss of neuronal
cells in the central nervous system which eventually con-
tributes to memory impairment. Moreover, as the result of
abnormal functioning in several areas of the patient’s brain
in the late stage of disease, AD can be fatal and it is offi-
cially ranked as the sixth-leading cause of death in the
United States (U.S.) in 2018 [24]. AD is suffered by 35–40
million patients worldwide and there is currently no
proven complete cure [25]. Although the exact pathogenic
mechanisms underlying AD remains unknown, the neuro-
transmitter acetylcholine and glutamate are potentially
considered as therapeutic targets and have been focused
since both neurotransmission systems were found aber-
rant in the brains of individuals with AD [26]. Drugs com-
monly used to treat AD include acetylcholinesterase
(AChE) inhibitors (e.g., galantamine and donepezil) and
N-methyl-D-aspartate (NMDA)-type glutamate receptor
antagonists (e.g., memantine). Nevertheless, these drugs
provide only symptomatic relief but not a cure. The
debate over the therapeutic benefits versus the side effects
and the financial cost of these drugs has continued for de-
cades [27–29]. The discovery of therapeutic, cost effective
AD drugs devoid of adverse side effects is a very active
area of research [30].
Besides disturbances of neurotransmitters, oxidative
stress and exacerbation of inflammatory responses have
been associated with AD as significant contributors to
neuronal damage and neurodegeneration [31–33]. Inter-
estingly, bacterial infection is now considered as a risk
or causative factor of AD by triggering chronic inflam-
mation in the brain that may subsequently promote the
initiation and progression of the disease [34–36]. Add-
itionally, the presence of bacteria in the brain may play a
role in the accumulation and deposition of amyloid beta
(Aβ) peptides, the major pathological hallmark of AD,
which these peptides may be recruited to the site of in-
fection due to their functions in innate immunity as an-
timicrobials [37, 38]. A dramatic reduction of cerebral
Aβ levels was observed when transgenic mouse model of
AD was in the absence of gut microbiota [39] or in the
prolonged shift of gut microbial composition induced by
broad-spectrum combinatorial antibiotic treatment [40].
Recent evidence using next generation sequencing
(NGS) analysis that observed an increase of bacterial
populations in post-mortem brains from patients with
AD, also supports the involvement of bacterial infection
in AD [41]. Hence, controlling AD-associated infections
by using compounds with bactericidal or antibacterial
activities was highlighted as an alternative strategy for
disease prevention and treatment [34, 35, 42, 43].
Medicinal plants can be of important natural resources
for novel agents that may constitute an alternative to the
present drugs used in the treatment of several illnesses
including AD [11]. Streblus asper Lour. is a well-known
medicinal plant that belongs to family Moraceae and dis-
tributes mainly over the region of Southeast Asia. Differ-
ent parts of the plant have been traditionally used for
various medicinal purposes such as treatment of fever,
toothache, filariasis, leprosy, snakebite, diarrhoea, piles,
epilepsy, epistaxis, heart disease, urinary tract com-
plaints, stomachache, obesity, skin diseases, wounds, and
cancer [44, 45]. It has also been used as an ingredient in
a traditional Thai formula for longevity [46]. Studies on
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the crude plant extract as well as the isolated com-
pounds have demonstrated that S. asper exhibits various
pharmacological properties including antioxidant, anti-
cancer [47], antimicrobial [48], antimalarial [49],
anti-filarial [50], anti-inflammation [51], and
anti-hepatitis B activities [52]. Moreover, the neuropro-
tective properties of S. asper leaf extracts in both in vivo
and in vitro models of neurodegenerative diseases were
recently reported [53, 54]. However, the active phyto-
chemical ingredients responsible for neuroprotection
have not been clearly identified. The main objective of
our research is to enhance the utilization of this plant
extract with the best efficacy for therapeutic applications
and facilitate the clarification of its active components.
This was achieved by first carrying out the fractionation
of the crude ethanolic extract of S. asper leaves using
liquid-liquid extraction based on pH properties of its
phytochemical constituents. The resulting fractions of
organic neutral, acidic, and basic components were in-
vestigated and compared to each other for their pharma-
cological potentials including antibacterial, antioxidant,
anti-AChE, and neuroprotective activities.
Methods
Chemicals and reagents
Acetylcholinesterase from electric eel (EC 3.1.1.7, type
V-S), bovine serum albumin (BSA), 1-naphthyl acetate,
Fast Blue B salt, galantamine, Tris-HCl, dimethyl sulfox-
ide (DMSO), Dulbecco’s modified Eagle’s medium
(DMEM), fetal bovine serum (FBS), 2,2′-Azino-bi-
s(3-ethylbenzothiazoline-6-sulfonic acid) diammonium
salt (ABTS), and 2,2-Diphenyl-1-picrylhydrazyl (DPPH)
were purchased from Sigma-Aldrich (St. Louis, MO,
USA). Phosphate buffer saline (PBS) and Penicillin/
Streptomycin solution were purchased from Hyclone
(Logan, Utah, USA). Trypsin-EDTA was purchased from
Gibco (Waltham, MA, USA). 3-(4,5-dimetylthiazo-
l-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) was pur-
chased from Bio Basic (Markham, Ontario, Canada).
L-ascorbic acid was purchased from Calbiochem (San
Diego, CA, USA). Mueller-Hinton broth was purchased
from Himedia laboratories (Mumbai, MH, India). Other
reagents used in extraction process were of analytical
grade.
Plant collection and identification
Leaves of S. asper were collected from the Princess
Maha Chakri Sirindhorn Herbal Garden (Rayong Prov-
ince, Thailand). The plant was authenticated by Profes-
sor Dr. Thaweesakdi Boonkerd and deposited in the
herbarium of Kasin Suvatabhandhu (Department of Bot-
any, Faculty of Science, Chulalongkorn University,
Thailand) under voucher number A013419 (BCU).
Preparation of crude extract
After collection, the ethanolic extract of S. asper leaves
was prepared as previously described [54]. In brief, the
dry powered plant material (0.73 kg) was soaked in
100% ethanol (7.3 L) with a 1:10 sample-solvent ratio for
48 h at room temperature (RT) in the dark with con-
tinuous shaking. The resulting liquid extract was filtered
and concentrated using rotary evaporator to give 29.44 g
of crude extract. Part of this concentrated extract was
dissolved in DMSO, passed through a 0.2-μm filter, and
stored at − 20 °C as a stock solution for evaluating bio-
logical activities.
Preparation of acid-base fractions
For efficient acid-base extraction, crude ethanolic extract
of S. asper leaves (29.44 g) was firstly dissolved in ethyl
acetate (EtOAc) (700 mL) and partitioned with distilled
water (700 mL). The resulting organic solution was con-
centrated, re-dissolved in dioxane (200 mL) and slowly
added dropwise of distilled water (80 mL) while stirring
continuously to induce the precipitation of chlorophyll
[55]. Then, the precipitates were removed by three
rounds of centrifugation (4400 rpm for 20 min) with
each round being followed by filtration through filter pa-
pers. The chlorophyll-removed extracts were combined,
and solvents were removed to give a thick paste. The
paste was used for fractionation into neutral, acidic, and
basic fractions based on the method of alkaloid extrac-
tion previously used by Mungkornasawakul et al. [56],
with some modifications. The procedure of acid-base ex-
traction was summarized in Fig. 1. The crude paste was
dissolved in EtOAc (150 mL) and extracted with 5%
hydrochloric acid (HCl) (700 mL). The ethyl acetate (Or-
ganic phase-1) layer was separated from the 5% HCl
(Aqueous phase-1) layer and set aside for basic extrac-
tion. The 5% HCl solution was made basic (pH 10) with
10 M sodium hydroxide (NaOH) and the resulting solu-
tion was further extracted with EtOAc (200 mL × 2).
The ethyl acetate extracts were washed with saturated
NaCl solution and dried over anhydrous potassium car-
bonate (K2CO3). The solvent was removed to afford the
basic fraction.
Simultaneously, ethyl acetate (Organic phase-1) layer
was extracted with an equal volume of 0.5 M NaOH so-
lution. The top organic layer (Organic phase-2) was sep-
arated from the aqueous NaOH layer (Aqueous
phase-2), then washed with a saturated solution NaCl
and dried over anhydrous sodium sulfate (Na2SO4) and
the solvent was removed under reduced pressure to af-
ford the neutral fraction. Finally, the remaining the
aqueous NaOH layer (Aqueous phase-2) was then acid-
ified to pH 1 with 5% HCl and extracted with EtOAc
(200 mL × 2). The combined ethyl acetate extracts were
washed with a saturated solution NaCl and dried over
Prasansuklab et al. BMC Complementary and Alternative Medicine  (2018) 18:223 Page 3 of 13
anhydrous Na2SO4, and the solvent was removed under
reduced pressure to afford the acidic fraction. Parts of
three fractions obtained after acid-base extraction were
dissolved in DMSO, filtered through a 0.2-μm filter, and
stored at − 20 °C as a stock solution for evaluating
biological activities.
GC-MS analysis
Analysis of volatile chemical constituents was performed
using Agilent 6890 gas chromatograph fitted with an
Agilent HP-5 MS fused-silica capillary column (5% polysil-
phenylene, 95% polydimethylsiloxane column, 30 m×
0.25 mm, i.d. 0.25 μm film thickness), coupled to an Agilent
5973 N mass selective detector with electron-ionization
(EI) source (Agilent Technologies, Palo Alto, CA, USA).
The samples were dissolved in ethyl acetate and injected
automatically in the split mode with a split ratio of 1:25 and
injection volume of 1 μL. Helium was used as the carrier
gas at a constant flow rate of 1.2 mL/min. The total run
time was 10.8 min. The column oven temperature was
programmed initially at 50 °C for 2 min. Then, it was raised
to 290 °C with a rate of 50 °C/min and held at 290 °C for
4 min. The mass spectrometer was operated with ionization
energy of 70 eV, ion source temperature of 230 °C, detector
temperature of 150 °C, and in the scan mode over the mass
range of m/z 40–450. The compounds were identified by
matching their recorded retention times and mass spectral
patterns with the NIST mass spectral library (NIST08.L).
Determination of antibacterial activity
The antibacterial activity was determined by broth
microdilution according to CLSI guidelines. The test
medium was cation-adjusted Mueller-Hinton broth
(CAMHB). Test Medium was used for S. aureus
ATCC25923, B. subtilis SU5, E. coli MG1655 and P.
aeruginosa PA14. Serially diluted concentrations of
samples or standard antibiotic ampicillin (a positive
inhibition control) were tested using a 96 well plate, which
was inoculated with a bacterium cell concentration of
approximately 5 × 105 CFU. The CAMHB medium plus
sample without inoculum was used as a negative control.
After 20 h of incubation at 37 °C statically, the minimum
inhibitory concentration (MIC) was defined as the lowest
concentration of compound that showed 95% cell growth
inhibition, determined by measuring absorbance at
595 nm. The experiment was performed in biological
triplicates.
Determination of antioxidant activity
The antioxidant activity was evaluated in vitro using the
DPPH and ABTS radical scavenging assays modified for
a 96-well microtiter plate format as described previously
[54]. Briefly, various concentrations of samples or
Fig. 1 Acid-Base extraction of S. asper ethanolic extract
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ascorbic acid (a positive control) in absolute ethanol and
the DPPH• or ABTS• + working solution were mixed in
a ratio of 9:1 (v/v) in a 96 well-plate. The working solu-
tion plus absolute ethanol was used as a negative con-
trol. The reaction mixture was incubated in the dark at
RT for 15 min or 30 min and the absorbance was re-
corded using a microplate reader (BioTek Instruments,
Winooski, VT, USA) at 517 nm or 734 nm for DPPH or
ABTS assay, respectively. Radical scavenging activity was
calculated as the percent inhibition of free radicals using
the following equation: % Inhibition = 100 - [(Abs of the
sample - Abs of blank) × 100/ Abs of control]. The anti-
oxidant capacity of each sample was also compared with
those of ascorbic acid (vitamin C) and was expressed as
vitamin C equivalent antioxidant capacity (VCEAC) in
mg per g of dry weight sample.
Determination of anti-acetylcholinesterase activity
The AChE inhibitory activity was screened by using
thin-layer chromatography (TLC)-direct bioautographic
assay adapted from Marston’s method [57]. This assay is
based on the activity of AChE in converting the sub-
strate 1-naphthyl acetate to 1-naphthol, which in turn
reacts with the chromogenic agent Fast Blue B salt to
produce a purple-coloured diazonium dye. The working
solution of AChE was prepared by dissolving 1.21 mg of
lyophilized powder of AChE from electric eel in 135 mL
of 0.05 M Tris-HCl buffer at pH 7.8 with 150 mg of bo-
vine serum albumin. The silica gel F254 TLC plates
(Merck, Darmstadt, Germany) were prewashed with
acetone and thoroughly dried before use. Briefly, 1 mg
of each sample was dissolved in ethyl acetate
(1000 ppm), 6.7 μL (6.7 μg) of the solution was spotted
on a pre-washed TLC plate and developed with the solv-
ent system of hexane: ethyl acetate (7:3, v/v). Then,
3.3 μL (0.3 μg) of galantamine solution (0.1 mg/mL,
100 ppm) was also applied on the plate as a positive
control. After completely air-dried, the TLC plates were
then saturated by spraying with the enzyme stock solu-
tion (6.71 U/mL) and incubated in a humidified chamber
for 20 min at 37 °C. Afterwards, the enzyme activity was
detected by spraying with the mixture solution contain-
ing a part of 13.8 mM of 1-naphthyl acetate in ethanol
plus four parts of 5.27 mM of Fast Blue B salt in distilled
water, onto the moist TLC plates. The presence of po-
tential compounds with anti-AChE activity was deter-
mined as the appearance of white (clear) spot on the
purple-coloured background.
Cell culture and treatments
Immortalized mouse hippocampal HT22 cell line, a kind
gift from Prof. David Schubert at the Salk Institute (San
Diego, CA, USA), was grown in DMEM supplemented
with 10% FBS and 1% Penicillin/Streptomycin solution.
The cells were maintained at 37 °C in a 5% CO2 humidi-
fied incubator and sub-cultured when they reach about
80–90% confluency. For cell viability assay, HT22 cells
were seeded onto a 96-well microtiter plate at a density
of 6 × 103 cells per well and allowed to attach.
Twenty-four hours later, the cells were incubated for
additional 18 h with the medium in the absence or pres-
ence of 5 mM glutamate or in the presence of 5 mM
glutamate plus various concentrations of tested extracts.
Determination of cell viability
The cell viability of HT22 cells was measured by the
MTT colourimetric assay to determine the neuroprotec-
tive property of tested extracts against glutamate cyto-
toxicity. In the assay, untreated HT22 cells served as a
negative control, while cells treated with 100% DMSO
served as a positive control. MTT was prepared as a
stock solution of 5 mg/ml in PBS, pH 7.2, sterilized
through a 0.2-μm filter, and stored at − 20 °C. At the
end of incubation time, 20 μL of MTT solution was
added to each well, followed by incubation at 37 °C for
4 h. The medium containing MTT solution was then re-
moved and 100 μL of DMSO was replaced in each well
to dissolve the purple formazan crystals produced from
viable cells. The absorbance was read by a microplate
reader (BioTek Instruments, Winooski, VT, USA) at
550 nm. The percentage of cell viability was calculated
by the following formula: Cell viability (%) = [Abs of
treated cells/ Abs of untreated cells (control)] × 100.
Statistical evaluation
For antioxidant and cell viability assays, the experiments
were performed at least in triplicate and the data are
represented as means ± standard deviation (SD) or
means ± standard error of the mean (SEM) as indicated
in figures. The statistical analyses were performed using
SPSS software version 17.0 (SPSS Inc., Chicago, IL,
USA). Pearson’s correlation test was conducted to evalu-
ate the relationship between two antioxidant assays.
One-way analysis of variance (ANOVA), followed by the
post hoc Tukey HSD multiple comparison tests was
employed to determine the differences among group
means. P values < 0.05 were considered statistically
significant.
Results
Extraction yields and the chemical composition of the S.
asper fractions obtained by acid-base extraction
Acid-base extraction of 29.44 g of the S. asper ethanolic
leaf extract yielded 0.158 g (0.54%, w/w) of basic frac-
tion, 0.476 g (1.62%, w/w) of acidic fraction, and 1.128 g
(3.83%, w/w) of neutral fraction. Figure 2 shows the
color of crude leaf extract and the fractions obtained.
The brownish and yellowish colors observed in the
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acid-base fractions suggested that most of the chloro-
phyll (green pigment) in the leaves was successfully re-
moved from crude leaf extract. Each fraction was further
analyzed by GC-MS and tentative compounds were
identified by comparing their GC retention indices and
mass spectral patterns with the database at the match
quality value above 80%. A total of 11 tentative volatile
compounds were proposed including terpenoids, ste-
roids, phenolics, fatty acids, nitrogen-sulfur containing
compounds, as well as lipidic plant hormone were listed
in Table 1.
Antibacterial activity of the S. asper fractions
The antibacterial activity of the crude S. asper ethanolic
extract and its acid-base fractions are presented in
Table 2. Amongst the three fractions examined, the
acidic fraction exhibited the strongest antibacterial activ-
ity against two gram-positive bacteria S. aureus and B.
subtilis, with a MIC value of 125 μg/mL. However, at the
highest tested concentration of 1000 μg/mL, none of the
three fractions showed inhibition of bacterial growth at
≥95% against the two gram-negative bacteria E. coli and
P. aeruginosa.
Antioxidant capacity of the S. asper fractions
The DPPH radical scavenging activities at 1 mg/mL con-
centration of the crude S. asper ethanolic extract and its
acid-base fractions varied ranging from 8.94 to 17.16%
(10.00 to 18.88 mg VCEAC/g dry weight), whereas their
scavenging activities on ABTS radical were found much
higher than those on DPPH radical in the range of 34.29
to 48.45% (29.02 to 39.45 mg VCEAC/g dry weight)
(Table 3). All the crude extract and its acid-base frac-
tions exhibited concentration-dependent scavenging ef-
fects towards the DPPH (Fig. 3a) and ABTS radicals
(Fig. 3b). Amongst all the extract and three fractions ex-
amined, the acidic fraction possessed the strongest anti-
oxidant capacity, while the neutral fraction showed
relatively weak antioxidant property based on the results
from both DPPH and ABTS assays. The descending
order of antioxidant potential among three isolated frac-
tions was as acidic > basic > neutral. Pearson’s correl-
ation revealed a significant positive moderate
relationship (r = 0.7275, p = 0.0014) between the DPPH
and ABTS antioxidant activities of all tested samples
(Fig. 3c).
Neuroprotective activity of the S. asper fractions
The neuroprotective properties of the crude S. asper
ethanolic extract and its acid-base fractions were evalu-
ated against glutamate toxicity in hippocampal neuronal
HT22 cells. The crude extract, neutral and acidic frac-
tions did not exhibit a noticeable cytotoxic effect on
HT22 cells whose cell viabilities were above 90% follow-
ing exposure to varying concentrations ranging from 1
to 50 μg/mL (Fig. 4a). The basic fraction became toxic
to the cells when the concentration was increased above
25 μg/mL. Treatment of HT22 cells with 5 mM glutam-
ate significantly reduced cell viability by approximately
80%. However, co-treatment with crude extract, either
neutral fraction or basic fraction significantly increased
the viability of glutamate-treated HT22 cells in a
dose-dependent manner, as determined using MTT assay
(Fig. 4b) and examined morphologically under a phase
contrast microscope (Fig. 4c). The cytotoxic effect of
glutamate could be considerably restored (comparable to
about 80% of the control level) in the presence of the
crude extract, neutral fraction, and the basic fraction at
the minimum concentration of 25, 5, and 10 μg/mL, re-
spectively. The acidic fraction did not show any protect-
ive effects against glutamate-induced cytotoxicity.
Anti-acetylcholinesterase activity of the S. asper fractions
TLC chromatogram of the neutral fraction isolated at
least 9 visible spots of constituents under visible light
(Fig. 5a) and confirmed by visualizing under
short-wavelength UV radiation (254 nm), in which three
of them were also observed by KMnO4 staining (Fig.
5b). However, in the acidic fraction, there was only one
spot visible under visible light (Fig. 5a), while three more
spots could be only viewed under UV light, in which
one of them was also observed by KMnO4 staining (Fig.
5b). Using a similar solvent system to that employed in
the experiment mentioned above, the AChE inhibitory
properties of the neutral and acidic fractions were fur-
ther evaluated on TLC plates by the bioautographic
method and are shown in Fig. 5c. In this assay, the white
spot of inhibition on a dark purple background of the
plate represented the chemical components with AChE
inhibitory activity. A total of three chemical constituents
corresponding to AChE inhibitory activity in the neutral
and acidic fractions were found. TLC bioautogram of
the neutral fraction showed one spot of inhibition with
Fig. 2 Crude ethanolic extract of S. asper leaves and its
acid-base fractions
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Table 1 GC-MS analysis of the volatile components presented in the S. asper fractions
Fraction Retention time (min) Relative area (%) Tentative identification Match quality (%)
Neutral 6.111 2.6 Dihydroactinidiolide 94
6.548 5.5 Cadalene 80
6.696 11.7 n.i. –
7.124 7.0 Benzothiazole, 2-(2-hydroxyethylthio)- 99
7.466 5.9 n.i. –
8.370 9.4 Cholest-14-en-3-ol, 4-methyl-, (3.beta.,4.alpha.,5.alpha.)- 93
8.417 10.8 n.i. –
8.612 7.4 2,4-Bis(1-phenylethyl)phenol 86
10.072 7.3 n.i. –
Acidic 5.531 0.6 4-Hydroxybenzaldehyde 91
5.683 0.2 Vanillin 96
6.477 0.3 (+/−)-Jasmonic acid 95
6.543 3.6 Cadalene 83
6.686 3.1 n.i. –
7.010 2.2 Palmitic acid 99
7.114 6.9 Benzothiazole, 2-(2-hydroxyethylthio)- 98
7.457 12.6 Linolenic acid 99
7.485 8.5 n.i. –
8.355 6.8 Cholest-14-en-3-ol, 4-methyl-, (3.beta.,4.alpha.,5.alpha.)- 91
8.398 7.2 n.i. –
8.593 5.8 2,4-Bis(1-phenylethyl)phenol 93
Basic 5.421 1.6 n.i. –
6.543 2.2 Phenol, 2-(1-phenylethyl)- 91
6.686 30.1 n.i. –
6.762 4.9 n.i. –
7.109 6.0 Benzothiazole, 2-(2-hydroxyethylthio)- 99
7.295 8.2 n.i. –
7.471 12.4 n.i. –
8.350 4.2 n.i. –
8.398 4.6 n.i. –
8.588 3.3 Phenol, 2,4-bis(1-phenylethyl)- 91
n.i. Not identified
Table 2 Antibacterial activities of crude ethanolic extract of S. asper leaves and its fractions against a range of microorganisms
determined by the broth microdilution method
Microorganisms Minimum inhibitory concentration (MIC) in μg/mL
Crude extract Neutral fraction Acidic fraction Basic fraction
Gram-positive bacteria
Staphylococcus aureus (ATCC25923) 1000 1000 125 1000
Bacillus subtilis (SU5) 1000 250 125 500
Gram-negative bacteria
Escherichia coli (MG1655) > 1000 > 1000 > 1000 > 1000
Pseudomonas aeruginosa (PA14) > 1000 > 1000 > 1000 > 1000
MIC values are the lowest concentrations at which at least 95% bacterial growth reduction
The tested concentration of samples ranged from 125 to 1000 μg/mL
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Rf value of 0.44 and positive staining for KMnO4 (Fig.
5b and c). TLC bioautogram of the acidic fraction
showed two spots of inhibition with Rf values of 0.15
and 0.55. The spot with Rf 0.15 was also positively
stained with KMnO4 (Fig. 5b and c).
Discussion
The current available medications can only reduce the
severity of AD in certain patient groups, since there has
been no complete cure known for it. Importantly, AD
can be fatal and is now recognized as one of the major
global health problems [24]. Therefore, its prevalence
continues to rise rapidly, along with the burden on pub-
lic healthcare costs. This has a long-term impact on the
socio-economic development of the developing coun-
tries. In challenging this difficult situation, a number of
researchers have put a considerable effort for decades in
search of alternative treatment methods. Research in the
Table 3 Antioxidant capacities of the crude ethanolic extract of S. asper leaves and its fractions determined by the DPPH and ABTS
scavenging assays
Sample DPPH scavenging assay ABTS scavenging assay
%Radical Scavenging activity (of 1 mg/
mL sample)
mg VCEAC/g dry weight
sample
%Radical Scavenging activity (of 1 mg/
mL sample)




16.58 ± 1.33a 18.37 ± 1.25a 37.69 ± 1.81a 31.52 ± 1.63a
Neutral
fraction
8.94 ± 0.78b 10.63 ± 1.38b 34.29 ± 1.56b 29.02 ± 1.43b
Acidic
fraction
17.16 ± 1.74a 18.88 ± 1.39a 48.45 ± 1.55c 39.45 ± 1.43c
Basic fraction 8.94 ± 1.62b 10.00 ± 0.77b 39.23 ± 0.66a 32.66 ± 0.84a
Results are expressed as mean ± SD of at least three replicates
Different superscript letters in the same column indicate a significant difference between the means by one-way ANOVA (p < 0.05) and the same letter indicates
that there is no statistical difference
Fig. 3 The dose-response scavenging effects of the crude ethanolic extract of S. asper leaves and its fractions on a DPPH and b ABTS free
radicals. Data are expressed as means ± SD of 3–7 replicates. c Pearson’s correlation analysis between DPPH and ABTS scavenging activities based
on mean values of all samples analyzed
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field of herbal medicines has attracted much attention in
recent years, as it is believed to have advantages over
modern synthetic medicines with regard to efficacy,
safety, and cost for treatment of various medical prob-
lems. In Southeast-Asian countries, S. asper is a
well-known medicinal plant that has been traditionally
used for a variety of illness conditions despite limited
scientific evidence [44–46]. Interestingly, the ethanolic
leaf extracts of this plant have shown pharmacological
properties including antibacterial, neuroprotective, and
cognitive-improving effects that can be beneficial for the
treatment of AD [48, 53, 54]. However, the active con-
stituents responsible for those different activities have
not been clearly identified. In this study, the S. asper leaf
ethanolic extract was fractionated into fractions based
on pH properties and further evaluated for their antibac-
terial, antioxidant, anti-AChE, and neuroprotective activ-
ities. These biological activities could enhance the
therapeutic applications and facilitating activity-guided
isolation of active compounds of the S. asper extract in
the near future.
S. asper is commonly used to treat skin infections (e.g.
boils, leprosy, and wounds) and has beneficial role for
oral health and hygiene (e.g. relief of toothache,
antigingivatis, and strengthening teeth and gum) [44].
The bacterial species, which are most frequently found
associated with AD, are commonly found in oral cavities
such as spirochetes [42] and actinobacteria [41], thus it
is tempting us to investigate the antibacterial properties
of this plant. In this study, the crude ethanolic extract
was found to inhibit cell growth of gram-positive bac-
teria, S. aureus and B. subtilis. This effect was more pro-
found when the extract was fractionated to the acidic
fraction (MIC of 125 μg/mL) with at least eight-fold
higher than to ethanol crude extract. Neither the ethanol
extract nor acid-base fractions inhibit the growth of
gram-negative bacteria, E. coli and P. aeruginosa. Previ-
ous work by Wongkam et al. on the crude 50% ethanolic
extract, reported no antibacterial activity when tested on
the bacteria strains used in our study. Their study in-
stead showed weak MIC and MBC of 1.93 mg/mL
against Streptococcus mutans, Porphyromonas gingivalis,
and Actinobacillus actinomycetemcomitans; bacteria that
are commonly associated with dental caries and gingi-
vitis [48, 58, 59]. The source of plant collection and the
percentage of ethanol used for extraction may be the
critical factors for the different findings. Although
gram-negative bacteria are generally more harmful, some
(See figure on previous page.)
Fig. 4 Protective effects of the crude ethanolic extract of S. asper leaves and its fractions against glutamate-induced neuronal cell death. a
Relative MTT viability of HT22 cells exposed to various concentrations of extracts. ###P = 8.8 × 10− 5 for 25 μg/mL and ###P = 7.5 × 10− 6 for 50 μg/
mL of basic fraction vs. control. b Relative MTT viability of HT22 cells exposed to glutamate alone or glutamate combined with different
concentrations of extracts. ###P = 2.9 × 10− 11 vs. control; *P = 3.1 × 10− 2 and ***P = 2.9 × 10− 11 vs. glutamate-treated cells. c Representative
morphological images at 5X magnification (scale bar = 100 μm) of untreated HT22 cells (control), or cells treated with glutamate alone, or with
glutamate plus crude extract or fractions at 1 and 10 μg/mL. Data are expressed as means ± SEM of 4 independent experiments with 2–3
replicates each
Fig. 5 Anti-AChE activities of neutral and acidic fractions obtained from S. asper leaves. TLC chromatograms of neutral and acidic fractions (at
6.7 μg application) in a solvent system of hexane:ethyl acetate (7:3, v/v) were observed a under visible light, b by staining with KMnO4, and c by
bioautographic method for screening on AChE inhibitory activity, where white spots against the dark background represent the inhibition.
Galantamine (GA) was used as a positive control at 0.3 μg. Brackets indicate AChE inhibiting constituents
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of the gram-positive bacteria can also be pathogenic in
humans. S. aureus is one of the most common causes of
skin and nosocomial infections as well as other infec-
tions at various sites of the body (e.g. bone, joint, lung,
and gastrointestinal tract) with symptoms ranging from
minor to life-threatening [60]. Here, our study provides
supporting evidence for the use of acidic fraction from
SA leaves to treat gram-positive bacterial infections par-
ticularly caused by S. aureus. Moreover, the promising
antibacterial activity of the acidic fraction relative to
other fractions could be contributed by the action of its
major volatile component, linolenic acid (Table 1, [54]).
It has been demonstrated that long-chain unsaturated
fatty acids including linolenic acid exerted highly potent
activity against gram-positive bacteria [61–64].
Free radicals are groups of atoms with an unpaired
number of electrons residing in the outermost shell. The
majority of free radicals are generated from oxygen mol-
ecules and called reactive oxygen species (ROS). Once
formed in excess, these highly reactive free radicals can
cause damage, in the process called oxidative stress, to
important cellular components such as lipids, proteins
and nucleic acids, subsequently, alter the structures and
functions that are associated with various human dis-
eases including AD [65]. In general, these detrimental ef-
fects of free radicals can be counterbalanced by
antioxidants, which are naturally derived from plants. S.
asper can be considered as an alternative source for anti-
oxidants since this plant has been shown promising anti-
oxidant properties in both in vitro and in vivo [54, 66–
70]. In line with the previous reports, our present study
also revealed the antioxidant properties, like free radical
scavenging, in S. asper leaf extracts. The ethanol crude
extract, neutral, acidic and basic fractions exhibited rela-
tively two- to four-fold higher activities in the ABTS
assay than in the DPPH assay and the percentage of
scavenging activities determined in both assays were
moderately correlated (r = 0.73). The slight difference in
results could be probably due to the distinct solubility of
tested substances in water, as hydrophilic antioxidants
were found better reflected by the ABTS than the DPPH
assay [71, 72]. Interestingly, after fractionation of crude
ethanolic leaf extract, the scavenging activities on DPPH
and ABTS radicals were found significantly higher in the
acidic fraction when compared to the crude extract and
other fractions, while the neutral fraction showed the
lowest antioxidant capacity in both assays. These find-
ings suggest that the components with antiradical activ-
ity in S. asper leaves are majorly in acidic and
water-soluble forms. Nevertheless, the DPPH and ABTS
radicals used in this study are uncommonly found in the
human body, the antioxidant capacity has to be further
investigated using ROS, which are produced as by-products
during cellular metabolism such as superoxide radicals
(O2•−), hydrogen peroxide (H2O2), or highly reactive hy-
droxyl radicals (OH•) for a better idea.
In an effort to develop a more effective treatment for
AD, several studies have been searching for new thera-
peutic targets underlying the disease pathology. Apart
from the cholinergic hypothesis that has been proposed
in the etiology of AD for several decades [73], growing
evidence links oxidative glutamate toxicity (or oxytosis)
to AD by supporting that glutamate-induced neuronal
cell death via non-receptor-mediated oxidative toxicity
pathway involves in the pathogenic mechanism of neu-
rodegeneration [74–76]. Hence, targeting towards the
glutamate-mediated oxidative toxicity pathway may offer
a new approach for treating AD as well as other neuro-
degenerative diseases. In accordance with our previous
results, the present study demonstrated that crude etha-
nolic extract from S. asper leaves exerted neuroprotec-
tive property against glutamate-induced HT22 neuronal
cell death [54]. This protective activity was also found
higher following fractionation of crude ethanolic leaf ex-
tract. The strongest protective activity against glutamate
toxicity in HT22 cells was observed in the neutral frac-
tion, wherein the minimum concentration showing re-
covery of 80% cell viability was five-fold lower than that
of the crude extract. Interestingly, TLC bioautography
also suggested that neutral fraction contains at least one
compound with AChE inhibitory activity with minimum
inhibitory concentration requirement of approximately
6.7 μg. Therefore, this finding indicates that neutral frac-
tion can be further developed as a potential multi-target
agent for AD treatment. However, due to the weak anti-
radical activity of neutral fraction, it may exert neuro-
protective capacity against glutamate-induced oxidative
damage via other antioxidative mechanisms. For in-
stance, induction of nuclear translocation of nuclear fac-
tor erythroid 2-related factor 2 (Nrf2) is a protective
pathway proposed in our previous work [54].
Conclusions
Our findings have demonstrated the therapeutic poten-
tial of three acid-base fractions extracted from the leaf
part of S. asper as promising natural source for neuro-
protective agents with additional actions of antibacterials
and antioxidants, along with AChE inhibitors. Further
studies should aim to isolate bioactive substances from
neutral and acidic fractions and identify the mechanisms
underlying their actions, which can be used to develop
new natural agents as therapeutic drugs for the treat-
ment of AD.
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